



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

December 21, 2004

Docket No. 03022173
Control No. 135737

License No. 29-20974-01

John E. Pugh
Business Manager
Hopewell Radiology Group, L.P.
3674 Route 27, Suite D
Kendall Park, NJ 08824-1090

SUBJECT: HOPEWELL RADIOLOGY GROUP, L.P., ISSUANCE OF LICENSE
AMENDMENT, CONTROL NO. 135737

Dear Mr. Pugh:

This refers to your license amendment request. Enclosed with this letter is the amended license. Please note that your license was written in a format compatible with the revised 10 CFR Part 35, dated April 24, 2002 (enclosed). In addition, please note that we could not process your request to delete the depleted uranium from your license as you did not supply a confirmation of receipt for this material by an authorized recipient.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. Please note the last condition on your license indicates that, "This license condition applies only to those procedures that are required to be submitted in accordance with the regulations." Therefore, any procedures submitted that were not required by regulation to be submitted, e.g., calibration of dose calibrators, will not be considered a part of your license and were not reviewed during the licensing process. These procedures will be reviewed during inspections, as necessary. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the NRC Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or pdrc@nrc.gov.

J. Pugh
Hopewell Radiology Group, L.P.

2

Thank you for your cooperation.

Sincerely,

Original signed by Michelle Beardsley

Michelle Beardsley
Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosures:

1. Amendment No. 13
2. 10 CFR Part 35

J. Pugh
Hopewell Radiology Group, L.P.

3

Ra

DOCUMENT NAME: E:\Filenet\ML043560086.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI		DNMS/RI			
NAME	MBeardsley/MRB							
DATE	12/21/04							

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Hopewell Radiology Group 2. 3674 Route 27 Kendall Park, New Jersey 08824-1090		In accordance with the letter dated September 29, 2004, 3. License number 29-20974-01 is amended in its entirety to read as follows:	
		4. Expiration date June 30, 2012	
		5. Docket No. 030-22173 Reference No.	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 40 millicuries	
D. Gadolinium 153 permitted by 10 CFR 35.500	D. Sealed sources (DuPont Pharma Model NES 8412 or North American Scientific Model MED 3601)	D. 300 millicuries per source and 2 curies total	
E. Depleted Uranium	E. Metal	E. 46 kilograms	

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
29-20974-01

Docket or Reference Number
030-22173

Amendment No. 13

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.
- D. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
- E. Shielding in the ADAC MCD/AC device.

CONDITIONS

- 10. Licensed material may be used only at the licensee's facilities at 9 Center Drive, Jamesburg, New Jersey.
- 11. The Radiation Safety Officer for this license is Robert B. Berger, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users

Material and Use

Charles B. Howard, M.D.

35.100; 35.200; 35.300 except thyroid carcinoma;
35.500; depleted uranium

Arthur L. Fein, M.D.

35.100; 35.200; 35.500; 35.300 except thyroid
carcinoma; depleted uranium

Robert R. Ford, M.D.

35.100; 35.200; 35.500; depleted uranium

William M. Green, M.D.

35.100; 35.200; 35.500; 35.300 except thyroid
carcinoma; depleted uranium

Robert B. Berger, M.D.

35.100; 35.200; 35.500; 35.300 except thyroid
carcinoma; depleted uranium

Donald P. Rosen, M.D.

35.100; 35.200; 35.500; depleted uranium

Gwen E. Guglielmi, M.D.

35.100; 35.200; 35.500; depleted uranium

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
29-20974-01Docket or Reference Number
030-22173

Amendment No. 13

Authorized UsersMaterial and Use

Donald F. Denny, M.D.	35.100; 35.200; 35.500; depleted uranium
John Ghazi, M.D.	35.100; 35.200; 35.300 except thyroid carcinoma; 35.500; depleted uranium
Gregory A. Kaufmann, M.D.	35.100; 35.200; 35.500; depleted uranium
Gerard A. Compito, M.D.	35.100; 35.200; 35.500; depleted uranium
Edward M. Soffen, M.D.	35.300 except I-131; 35.500; depleted uranium
Andrew Greenberg, M.D.	35.300 except I-131; 35.500; depleted uranium
Eric S. Perlman, M.D.	35.100; 35.200; oral administration of sodium iodide Iodine 131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction; 35.500; depleted uranium
Barry John Perlman, M.D.	35.100; 35.200; 35.300; 35.500; depleted uranium
Matthew Colin Difazio, M.D.	35.100; 35.200; 35.500; depleted uranium
Jonathan Alan Lebowitz, M.D.	35.100; 35.200; 35.500; depleted uranium
David Youmans, M.D.	35.100; 35.200; 35.500; depleted uranium
Deborah Allen Fein, M.D.	35.100; 35.200; 35.500; depleted uranium
Douglas Allen Fein, M.D.	35.300 except I-131; 35.500; depleted uranium
Bernard B. O'Malley, M.D.	35.100; 35.200; 35.500; depleted uranium
Kerstin Slawek, M.D.	35.100; 35.200; 35.500; depleted uranium
Timothy S. Howard, M.D.	35.100; 35.200; 35.500; depleted uranium
William A. Parker, M.D.	35.100; 35.200; 35.500; depleted uranium
Robert M. Cardinale, M.D.	35.300; 35.500; depleted uranium
Rik S. Sen, M.D.	35.100; 35.200
Jeana S. Oh, M.D.	35.100; 35.200
Martha Nowell, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
29-20974-01Docket or Reference Number
030-22173

Amendment No. 13

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 18, 1991
 - B. Letter dated July 18, 1991
 - C. Letter dated September 16, 1998
 - D. Letter dated February 28, 2001
 - E. Letter dated February 26, 2002

For the U.S. Nuclear Regulatory Commission

Original signed by Michelle BeardsleyDate December 21, 2004
bbbbbbbbbbbbbbbbbbbbbbbbbbBy _____
Michelle Beardsley
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406